R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
7.12.2021 14:28:03 CET | news aktuell GmbH | Press release

RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.
Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/news-press
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Neato expands exchange programme for customers across Europe19.11.2026 13:35:39 CET | Press release
Wuppertal, 19 November 2026 – Neato Robotics is significantly expanding its exchange programme for Neato customers across Europe, with the support of the Vorwerk Group. The programme is available to eligible private customers who purchased a Neato robot after 1 October 2020.
Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI19.11.2026 11:00:00 CET | Press release
Aachen, Germany, November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, start-ups, and research institutions at FEV’s headquarters in Aachen, Germany, on November 25 and 26. The event will focus on the latest technological developments, specific fields of application, and the prerequisites for the widespread adoption of advanced robotics.
Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release
Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”
PARACELSUS MEDICAL UNIVERSITY: PHARMACY PROGRAM GOES INTERNATIONAL16.11.2026 09:00:00 CET | Press release
Starting in the fall of 2027, the “Pharmacy and Pharmaceutical Sciences” program will be the first English-taught pharmacy program in the German-speaking region to qualify students to work across a range of pharmacy roles and settings.
Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release
Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom


